Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis

Journal of Immunology

Volumn 152, Issue 11, 1994, Pages 5477-5484

  Piddlesden, S J ^a   Storch, M K ^b   Hibbs, M ^c   Freeman, A M ^c   Lassmann, H ^b   Morgan, B P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF VIENNA   (Austria)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRL 55730; COMPLEMENT; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C9; RECOMBINANT COMPLEMENT RECEPTOR 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG EFFICACY; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MALE; RATS; RATS, INBRED LEW; RECEPTORS, COMPLEMENT 3B; RECOMBINANT PROTEINS;

EID: 0028179910     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fligiel, S. E. G., K. J. Johnson, and P. A. Ward. 1988. The role of complement in immune complex-induced tissue injury. In The Complement System. K. Rother, and G. O. Till, eds. Springer, Berlin, pp. 487-504.
2. Morgan, B. P. 1990. The biological effects of complement activation. In Complement, Clinical Aspects and Relevance to Disease. Academic Press, London, pp. 36-56.
3. Morgan, B. P. 1989. Mechanisms of tissue damage by the membrane attack complex of complement. Complement Inflamm. 6:104.
4. Cochrane, C. G., H. J. Muller-Eberhard, and B. S. Aiken. 1970. Depletion of plasma complement in vivo by a protein of cobra venom: its effects on various biological functions. J. Immunol. 105:55.
5. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, G. R. Carson, M. F. Concido, M. D. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor Type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.
6. Homeister, J. W., P. S. Satoh, K. S. Kilgore, and B. R. Lucchesi. 1993. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. J. Immunol. 150: 1055.
7. Smith, E. F., D. E. Griswold, S. W. Egan, L. M. Hillegas, R. A. G. Smith, M. T. Hibbs, and R. Gagnon. 1993. Reduction of myocaraial reperfusion injury with human soluble complement receptor type 1 (BRL55730). Eur. J. Pharmacol. 236:477.
8. Pemberton, M., G. Anderson, V. Vetvicka, D. E. Justus, and G. D. Ross. 1993. Microvascular effects of complement blockade with soluble complement receptor CR1 on ischemia/reperfusion injury of skeletal muscle. J. Immunol. 150:5104.
9. Lindsay, T. F., J. Hill, F. Ortiz, A. Rudolph, C. R. Valeri, H. B. Hetchman, and F. D. Moore Jr. 1992. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion. Ann. Surg. 216:677.
10. Hill, J., T. F. Lindsay, F. Ortiz, G. C. Yeh, H. B. Hechtman, and F. D. Moore. 1992. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149:1723.
11. Pruitt, S. K., W. M. Baldwin, H. C. Marsh, S. S. Lin, C. G. Yeh, and R. R. Bollinger. 1991. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 52:868.
12. Mulligan, M. S., G. C. Yeh, A. R. Rudolph, and P. A. Ward. 1992. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J. Immunol. 148:1479.
13. Mulligan, M. S., J. C. Paulson, S. DeFrees, Z-L. Zheng, J. B. Lowe, and P. A. Ward. 1993. Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature 364:149.
14. Sanders, M. E., E. L. Alexander, C. L. Koski, M. M. Frank, and K. A. Joiner. 1987. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 138:2095.
15. Compston, D. A. S., B. P. Morgan, A. K. Campbell, P. Wilkins, G. Cole, N. D. Thomas, and B. Jasani. 1989. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 15:307.
16. Linington, C., B. P. Morgan, N. J. Scolding, S. J. Piddlesden, P. Wilkins, and D. A. S. Compston. 1989. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 112:895.
17. Piddlesden, S. J., H. Lassmann, I. Laffafian, B. P. Morgan, and C. Linington. 1990. Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clin. Exp. Immunol. 83:245.
18. Piddlesden, S. J., H. Lassmann, F. Zimprich, B. P. Morgan, and C. Linington. 1993. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol. 143:1.
19. Scolding, N. J., B. P. Morgan, W. A. J. Houston, C. Linington, A. K. Campbell, and D. A. S. Compston. 1989. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339:620.
20. Piddlesden, S. J., and B. P. Morgan. 1993. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J. Neuroimmunol. 48:169.
21. Hodgetts, J., I. Laffafian, and B. P. Morgan. 1990. Purification of C8 and C9 from rat serum. Complement Inflamm. 7:42.
22. Wing, M. G., D. J. Seilly, D. J. Bridgman, and R. A. Harrison. 1993. Rapid isolation and biochemical characterization of rat C1 and C1q. Mol. Immunol 30:433.
23. Whaley, K. 1985. Measurement of complement. In Methods in Complement for Clinical Immunologists. K. Whaley, ed. Churchill-Livingstone, Edinburgh, pp. 77-139.
24. Vass, K., H. Lassmann, H. Wekerle, and H. M. Wisniewski. 1986. The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis. Acta Neuropathol. 70:149.
25. Cyong, C. J., S. S. Witkin, B. Rieger, E. Barbarese, R. A. Good, and N. K. Day. 1982. Antibody-independent complement activation by myelin via the classical pathway. J. Exp. Med. 155:587.
26. Vanguri, P., and M. L. Shin. 1985. Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. J. Biol. Chem. 263:7228.